Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CAPRICOR THERAPEUTICS, INC.CAPR · Entity 5337 | Director | February 27, 2025 | March 01, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CAPRICOR THERAPEUTICS, INC.
Report date February 27, 2025 · Filed March 01, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 57,606 |
Reported balance
After 2025-02-27 transaction · row 1
1 source rowRow 1 · 2025-02-27 · Exercise / conversion · Acquired 750 · Balance 57,606 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.39 · Expires 2025-03-03 | Direct | 0 |
Reported balance
After 2025-02-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-02-27 · Exercise / conversion · Disposed 750 · Balance 0 F1: This option was granted on March 3, 2015 and was previously reported as covering 7,500 shares at an exercise price of $5.78 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice of $1.39 per share that occurred on February 12, 2020. F2: The shares were fully vested and exercisable as of March 3, 2015, the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on March 3, 2015 and was previously reported as covering 7,500 shares at an exercise price of $5.78 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice of $1.39 per share that occurred on February 12, 2020.
F2: The shares were fully vested and exercisable as of March 3, 2015, the date of grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
TESARO, Inc.
Report date January 22, 2019 · Filed January 22, 2019
Section 16 reporting ended · disclosed 2019-01-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 1
1 source rowRow 1 · 2019-01-22 · Other · Disposed 2,090 · Balance 0 F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement"). |
| Director Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-01-22 · Disposition to issuer · Disposed 4,052 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F3: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. |
| Director Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.36 · Expires 2024-06-01 | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-01-22 · Disposition to issuer · Disposed 25,000 · Balance 0 F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. |
| Director Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.77 · Expires 2025-06-01 | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-01-22 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. |
| Director Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.27 · Expires 2026-06-01 | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-01-22 · Disposition to issuer · Disposed 12,000 · Balance 0 F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. |
| Director Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $149.22 · Expires 2027-06-01 | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-01-22 · Disposition to issuer · Disposed 12,000 · Balance 0 F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. |
| Director Nonqualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.89 · Expires 2028-06-01 | Direct | 0 |
Reported balance
After 2019-01-22 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-01-22 · Disposition to issuer · Disposed 7,209 · Balance 0 F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. |
Filing footnotes · ownership attribution and instrument terms
F1: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement").
F2: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock.
F3: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share.
F4: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd]
F5: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2025 Filed Mar 1, 2025 00:30 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Exercise / conversionStock Option (Right to Buy) · Derivative | 750 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0001415889-25-006069 · form4-02282025_070201.xml · derivative · entry 2 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 750 shares Expires 2025-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: This option was granted on March 3, 2015 and was previously reported as covering 7,500 shares at an exercise price of $5.78 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice of $1.39 per share that occurred on February 12, 2020. F2 · derivative.exercise_date: The shares were fully vested and exercisable as of March 3, 2015, the date of grant. F1 · derivative.underlying_shares: This option was granted on March 3, 2015 and was previously reported as covering 7,500 shares at an exercise price of $5.78 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice of $1.39 per share that occurred on February 12, 2020. Read SEC document |
| February 27, 2025 Filed Mar 1, 2025 00:30 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Exercise / conversionCommon Stock | 750 | $1.39 | $1,042.50 |
DisclosureSEC source: 0001415889-25-006069 · form4-02282025_070201.xml · nonDerivative · entry 1 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,606 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:00 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 5,750 | $0.00 Strike: $14.96 | $0.00 |
DisclosureSEC source: 0001415889-25-000868 · form4-01062025_070105.xml · derivative · entry 3 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,750 Underlying: Common Stock · 5,750 shares Expires 2035-01-02 F3 · derivative.exercise_date: The shares of the award are fully vested and exercisable as of January 2, 2025, the date of the grant. The award pertains to annual board service. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:00 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 3,240 | $0.00 Strike: $14.96 | $0.00 |
DisclosureSEC source: 0001415889-25-000868 · form4-01062025_070105.xml · derivative · entry 2 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,240 Underlying: Common Stock · 3,240 shares Expires 2035-01-02 F2 · derivative.exercise_date: The shares of the award are fully vested and exercisable as of January 2, 2025, the date of the grant. The award pertains to annual board committee service. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:00 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 11,940 | $0.00 Strike: $14.96 | $0.00 |
DisclosureSEC source: 0001415889-25-000868 · form4-01062025_070105.xml · derivative · entry 1 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,940 Underlying: Common Stock · 11,940 shares Expires 2035-01-02 F1 · derivative.exercise_date: The shares vest 1/12th of the first day of each month, commencing February 1, 2025, with the last month vesting on December 31, 2025, until the stock option becomes fully vested and exercisable. The award pertains to annual board service. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Issuer if the reporting person's service to the Issuer terminates prior to vesting. Read SEC document |
| April 23, 2024 Filed Apr 25, 2024 13:15 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0001415889-24-011488 · form4-04252024_090402.xml · derivative · entry 2 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,000 Underlying: Common Stock · 30,000 shares Expires 2030-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares vested 1/48th of the first day of each month, commencing March 1, 2020. Read SEC document |
| April 23, 2024 Filed Apr 25, 2024 13:15 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Exercise / conversionCommon Stock | 30,000 | $1.39 | $41,700.00 |
DisclosureSEC source: 0001415889-24-011488 · form4-04252024_090402.xml · nonDerivative · entry 1 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,856 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 22:15 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 14,280 | $0.00 Strike: $5.12 | $0.00 |
DisclosureSEC source: 0001415889-24-000652 · form4-01042024_050110.xml · derivative · entry 3 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,280 Underlying: Common Stock · 14,280 shares Expires 2034-01-02 F3 · derivative.exercise_date: The shares of the award are fully vested and exercisable as of January 2, 2024, the date of the grant. The award pertains to annual board service. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 22:15 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 8,030 | $0.00 Strike: $5.12 | $0.00 |
DisclosureSEC source: 0001415889-24-000652 · form4-01042024_050110.xml · derivative · entry 2 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,030 Underlying: Common Stock · 8,030 shares Expires 2034-01-02 F2 · derivative.exercise_date: The shares of the award are fully vested and exercisable as of January 2, 2024, the date of the grant. The award pertains to annual board committee service. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 22:15 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 29,250 | $0.00 Strike: $5.12 | $0.00 |
DisclosureSEC source: 0001415889-24-000652 · form4-01042024_050110.xml · derivative · entry 1 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,250 Underlying: Common Stock · 29,250 shares Expires 2034-01-02 F1 · derivative.exercise_date: The shares vest 1/12th of the first day of each month, commencing February 1, 2024, with the last month vesting on December 31, 2024, until the stock option becomes fully vested and exercisable. The award pertains to annual board service. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Issuer if the reporting person's service to the Issuer terminates prior to vesting. Read SEC document |
| October 10, 2023 Filed Oct 12, 2023 13:15 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | PurchaseCommon Stock | 10,000 | $2.83 | $28,300.00 |
DisclosureSEC source: 0001415889-23-014099 · form4-10122023_091001.xml · nonDerivative · entry 1 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,856 Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 01:00 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,401 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0001415889-23-002649 · form4-02152023_080201.xml · derivative · entry 2 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,401 shares Expires 2023-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: This option was granted on February 22, 2013 and was previously reported as covering 14,015 shares at an exercise price of $0.37 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice to $1.39 per share that occurred on February 12, 2020. F2 · derivative.exercise_date: 25% of the shares vested immediately, with the remainder vesting monthly over 25 months commencing May 1, 2013. F1 · derivative.underlying_shares: This option was granted on February 22, 2013 and was previously reported as covering 14,015 shares at an exercise price of $0.37 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice to $1.39 per share that occurred on February 12, 2020. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 01:00 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Exercise / conversionCommon Stock | 1,401 | $1.39 | $1,947.39 |
DisclosureSEC source: 0001415889-23-002649 · form4-02152023_080201.xml · nonDerivative · entry 1 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,856 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 01:00 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 19,000 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001415889-23-000593 · form4-01052023_080132.xml · derivative · entry 3 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2033-01-03 F3 · derivative.exercise_date: The shares of the award are fully vested and exercisable as of January 3, 2023, the date of the grant. The award pertains to annual board service. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 01:00 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 11,870 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001415889-23-000593 · form4-01052023_080132.xml · derivative · entry 2 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,870 Underlying: Common Stock · 11,870 shares Expires 2033-01-03 F2 · derivative.exercise_date: The shares of the award are fully vested and exercisable as of January 3, 2023, the date of the grant. The award pertains to annual board committee service. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 01:00 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 37,770 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001415889-23-000593 · form4-01052023_080132.xml · derivative · entry 1 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,770 Underlying: Common Stock · 37,770 shares Expires 2033-01-03 F1 · derivative.exercise_date: The shares vest 1/12th of the first day of each month, commencing February 1, 2023, with the last month vesting on December 31, 2023, until the stock option becomes fully vested and exercisable. The award pertains to annual board service. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Issuer if the reporting person's service to the Issuer terminates prior to vesting. Read SEC document |
| March 08, 2022 Filed Mar 10, 2022 00:00 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,455 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0001415889-22-002812 · form4-03092022_070302.xml · derivative · entry 2 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,455 shares Expires 2022-04-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: This option was granted on April 27, 2012 and was previously reported as covering 154,555 shares at an exercise price of $0.37 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice to $1.39 per share that occurred on February 12, 2020. F2 · derivative.exercise_date: 25% of the shares vested immediately, with the remainder vesting 1/36th of the first day of each month commencing June 1, 2012. F1 · derivative.underlying_shares: This option was granted on April 27, 2012 and was previously reported as covering 154,555 shares at an exercise price of $0.37 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice to $1.39 per share that occurred on February 12, 2020. Read SEC document |
| March 08, 2022 Filed Mar 10, 2022 00:00 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Exercise / conversionCommon Stock | 15,455 | $1.39 | $21,482.45 |
DisclosureSEC source: 0001415889-22-002812 · form4-03092022_070302.xml · nonDerivative · entry 1 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,455 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 02:00 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 63,060 | $0.00 Strike: $3.18 | $0.00 |
DisclosureSEC source: 0001415889-22-000278 · form4-01042022_090129.xml · derivative · entry 1 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,060 Underlying: Common Stock · 63,060 shares Expires 2032-01-03 F1 · derivative.exercise_date: The shares vest 1/48th of the first day of each month, commencing February 1, 2022, until the stock option becomes fully vested and exercisable. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Issuer if the reporting person's service to the Issuer terminates prior to vesting. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:03 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 71,951 | $0.00 Strike: $3.74 | $0.00 |
DisclosureSEC source: 0001104659-21-001584 · tm211849-3_4seq1.xml · derivative · entry 1 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,951 Underlying: Common Stock · 71,951 shares Expires 2031-01-04 F1 · derivative.exercise_date: The shares vest 1/48th of the first day of each month, commencing February 1, 2021, until the stock option becomes fully vested and exercisable. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Issuer if the reporting person's service to the Issuer terminates prior to vesting. Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 20:33 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 83,000 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0001104659-20-071417 · tm2022128-3_4.xml · derivative · entry 1 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,000 Underlying: Common Stock · 83,000 shares Expires 2030-06-05 F1 · derivative.exercise_date: The shares vest 1/48th of the first day of each month, commencing March 1, 2020, until the stock option becomes fully vested and exercisable. The following stock option grant was approved by the Board on February 12, 2020 under the 2020 Plan, contingent upon stockholder approval of the 2020 Plan, which was obtained on June 5, 2020. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Issuer if the reporting person's service to the Issuer terminates prior to vesting. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:08 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Disposition to issuerStock Option (Right to Buy) · Derivative | 15,455 | Not disclosed Strike: $3.70 | Not disclosed |
DisclosureSEC source: 0001104659-20-022100 · tm208086d3_4.xml · derivative · entry 14 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,455 shares Expires 2022-04-27 F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share. F5 · derivative.exercise_date: The stock option award is fully vested and exercisable. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:08 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Disposition to issuerStock Option (Right to Buy) · Derivative | 1,401 | Not disclosed Strike: $3.70 | Not disclosed |
DisclosureSEC source: 0001104659-20-022100 · tm208086d3_4.xml · derivative · entry 13 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,401 shares Expires 2023-03-06 F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share. F5 · derivative.exercise_date: The stock option award is fully vested and exercisable. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:08 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Disposition to issuerStock Option (Right to Buy) · Derivative | 750 | Not disclosed Strike: $57.80 | Not disclosed |
DisclosureSEC source: 0001104659-20-022100 · tm208086d3_4.xml · derivative · entry 12 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 750 shares Expires 2025-03-03 F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share. F5 · derivative.exercise_date: The stock option award is fully vested and exercisable. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:08 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Disposition to issuerStock Option (Right to Buy) · Derivative | 2,437 | Not disclosed Strike: $31.20 | Not disclosed |
DisclosureSEC source: 0001104659-20-022100 · tm208086d3_4.xml · derivative · entry 11 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,437 shares Expires 2026-06-02 F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share. F5 · derivative.exercise_date: The stock option award is fully vested and exercisable. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:08 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Disposition to issuerStock Option (Right to Buy) · Derivative | 2,856 | Not disclosed Strike: $25.50 | Not disclosed |
DisclosureSEC source: 0001104659-20-022100 · tm208086d3_4.xml · derivative · entry 10 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,856 shares Expires 2027-01-03 F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share. F4 · derivative.exercise_date: 856 of the shares will vest 1/48th on the first day of each month, commencing February 1, 2017, until the stock option becomes fully vested and exercisable. The remaining 2,000 shares will vest 1/12th on the first day of each month, commencing February 1, 2017, with the last month vesting on December 31, 2017. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:08 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Disposition to issuerStock Option (Right to Buy) · Derivative | 3,050 | Not disclosed Strike: $15.70 | Not disclosed |
DisclosureSEC source: 0001104659-20-022100 · tm208086d3_4.xml · derivative · entry 9 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,050 shares Expires 2028-01-02 F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share. F3 · derivative.exercise_date: 1,050 of the shares will vest 1/48th on the first day of each month, commencing February 1, 2018, until the stock option becomes fully vested and exercisable. The remaining 2,000 shares will vest 1/12th on the first day of each month, commencing February 1, 2018, with the last month vesting on December 31, 2018. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:08 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Disposition to issuerStock Option (Right to Buy) · Derivative | 4,750 | Not disclosed Strike: $3.25 | Not disclosed |
DisclosureSEC source: 0001104659-20-022100 · tm208086d3_4.xml · derivative · entry 8 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,750 shares Expires 2029-08-08 F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share. F1 · derivative.exercise_date: 3,000 of the shares were vested on the date of grant. The remaining 1,750 shares will vest 1/48th on the first day of each month, commencing September 1, 2019, until the stock option becomes fully vested and exercisable. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:08 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 15,455 | Not disclosed Strike: $1.39 | Not disclosed |
DisclosureSEC source: 0001104659-20-022100 · tm208086d3_4.xml · derivative · entry 7 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,455 Underlying: Common Stock · 15,455 shares Expires 2022-04-27 F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share. F5 · derivative.exercise_date: The stock option award is fully vested and exercisable. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:08 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 1,401 | Not disclosed Strike: $1.39 | Not disclosed |
DisclosureSEC source: 0001104659-20-022100 · tm208086d3_4.xml · derivative · entry 6 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,401 Underlying: Common Stock · 1,401 shares Expires 2023-03-06 F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share. F5 · derivative.exercise_date: The stock option award is fully vested and exercisable. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:08 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 750 | Not disclosed Strike: $1.39 | Not disclosed |
DisclosureSEC source: 0001104659-20-022100 · tm208086d3_4.xml · derivative · entry 5 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750 Underlying: Common Stock · 750 shares Expires 2025-03-03 F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share. F5 · derivative.exercise_date: The stock option award is fully vested and exercisable. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:08 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 2,437 | Not disclosed Strike: $1.39 | Not disclosed |
DisclosureSEC source: 0001104659-20-022100 · tm208086d3_4.xml · derivative · entry 4 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,437 Underlying: Common Stock · 2,437 shares Expires 2026-06-02 F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share. F5 · derivative.exercise_date: The stock option award is fully vested and exercisable. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:08 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 2,856 | Not disclosed Strike: $1.39 | Not disclosed |
DisclosureSEC source: 0001104659-20-022100 · tm208086d3_4.xml · derivative · entry 3 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,856 Underlying: Common Stock · 2,856 shares Expires 2027-01-03 F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share. F4 · derivative.exercise_date: 856 of the shares will vest 1/48th on the first day of each month, commencing February 1, 2017, until the stock option becomes fully vested and exercisable. The remaining 2,000 shares will vest 1/12th on the first day of each month, commencing February 1, 2017, with the last month vesting on December 31, 2017. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:08 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 3,050 | Not disclosed Strike: $1.39 | Not disclosed |
DisclosureSEC source: 0001104659-20-022100 · tm208086d3_4.xml · derivative · entry 2 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,050 Underlying: Common Stock · 3,050 shares Expires 2028-01-02 F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share. F3 · derivative.exercise_date: 1,050 of the shares will vest 1/48th on the first day of each month, commencing February 1, 2018, until the stock option becomes fully vested and exercisable. The remaining 2,000 shares will vest 1/12th on the first day of each month, commencing February 1, 2018, with the last month vesting on December 31, 2018. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:08 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 4,750 | Not disclosed Strike: $1.39 | Not disclosed |
DisclosureSEC source: 0001104659-20-022100 · tm208086d3_4.xml · derivative · entry 1 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,750 Underlying: Common Stock · 4,750 shares Expires 2029-08-08 F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share. F1 · derivative.exercise_date: 3,000 of the shares were vested on the date of grant. The remaining 1,750 shares will vest 1/48th on the first day of each month, commencing September 1, 2019, until the stock option becomes fully vested and exercisable. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting. Read SEC document |
| August 08, 2019 Filed Aug 10, 2019 01:00 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (right to buy) · Derivative | 4,750 | $0.00 Strike: $3.25 | $0.00 |
DisclosureSEC source: 0001144204-19-038999 · tv527330_form4.xml · derivative · entry 1 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,750 Underlying: Common Stock · 4,750 shares Expires 2029-08-08 F1 · derivative.exercise_date: 3,000 of the shares shall vest immediately. The remaining 1,750 shares will vest 1/48th on the first day of each month, commencing September 1, 2019, until the stock option becomes fully vested and exercisable. However, the option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting. Read SEC document |
| January 22, 2019 Filed Jan 22, 2019 09:56 UTC | TESARO, Inc. TSRO · Entity 160894 | Disposition to issuerDirector Nonqualified Stock Option (right to buy) · Derivative | 7,209 | Not disclosed Strike: $46.89 | Not disclosed |
DisclosureSEC source: 0001123292-19-000164 · edgar.xml · derivative · entry 7 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,209 shares Expires 2028-06-01 F4 · price: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · price: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · derivative.exercise_date: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. Read SEC document |
| January 22, 2019 Filed Jan 22, 2019 09:56 UTC | TESARO, Inc. TSRO · Entity 160894 | Disposition to issuerDirector Nonqualified Stock Option (right to buy) · Derivative | 12,000 | Not disclosed Strike: $149.22 | Not disclosed |
DisclosureSEC source: 0001123292-19-000164 · edgar.xml · derivative · entry 6 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2027-06-01 F4 · price: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · price: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · derivative.exercise_date: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. Read SEC document |
| January 22, 2019 Filed Jan 22, 2019 09:56 UTC | TESARO, Inc. TSRO · Entity 160894 | Disposition to issuerDirector Nonqualified Stock Option (right to buy) · Derivative | 12,000 | Not disclosed Strike: $47.27 | Not disclosed |
DisclosureSEC source: 0001123292-19-000164 · edgar.xml · derivative · entry 5 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2026-06-01 F4 · price: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · price: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · derivative.exercise_date: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. Read SEC document |
| January 22, 2019 Filed Jan 22, 2019 09:56 UTC | TESARO, Inc. TSRO · Entity 160894 | Disposition to issuerDirector Nonqualified Stock Option (right to buy) · Derivative | 10,000 | Not disclosed Strike: $60.77 | Not disclosed |
DisclosureSEC source: 0001123292-19-000164 · edgar.xml · derivative · entry 4 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2025-06-01 F4 · price: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · price: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · derivative.exercise_date: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. Read SEC document |
| January 22, 2019 Filed Jan 22, 2019 09:56 UTC | TESARO, Inc. TSRO · Entity 160894 | Disposition to issuerDirector Nonqualified Stock Option (right to buy) · Derivative | 25,000 | Not disclosed Strike: $26.36 | Not disclosed |
DisclosureSEC source: 0001123292-19-000164 · edgar.xml · derivative · entry 3 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2024-06-01 F4 · price: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · price: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option that was outstanding and unvested immediately prior to the Effective Time vested in full at the Effective Time. [Cont'd] F5 · derivative.exercise_date: [Continuation] Each option that was outstanding immediately prior to the Effective Time that had an exercise price per share less than $75.00 was cancelled in exchange for the right of the holder to receive (without interest) an amount in cash (less applicable withholding of taxes required by applicable law) equal to the product of (i) the total number of shares of TESARO common stock subject to the unexercised portion of such option immediately prior to the Effective Time (determined after giving effect to the accelerated vesting described in the previous sentence) multiplied by (ii) the excess, if any, of $75.00 over the applicable exercise price per share under such option. Each option that was outstanding immediately prior to the Effective Time with an exercise price per share that is greater than or equal to $75.00 was cancelled at the Effective Time, and the holder of such option is not entitled to any payment in exchange for the cancellation of the option. Read SEC document |
| January 22, 2019 Filed Jan 22, 2019 09:56 UTC | TESARO, Inc. TSRO · Entity 160894 | Disposition to issuerDirector Restricted Stock Units · Derivative | 4,052 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-19-000164 · edgar.xml · derivative · entry 2 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,052 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of TESARO common stock. F3 · price: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. F3 · derivative.exercise_date: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. F3 · derivative.expiration_date: These restricted stock units were cancelled pursuant to the Merger Agreement at the effective time of the Merger (the "Effective Time") in exchange for a cash payment of $75.00 per share. Read SEC document |
| January 22, 2019 Filed Jan 22, 2019 09:56 UTC | TESARO, Inc. TSRO · Entity 160894 | OtherCommon Stock | 2,090 | $75.00 | $156,750.00 |
DisclosureSEC source: 0001123292-19-000164 · edgar.xml · nonDerivative · entry 1 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Tendered in connection with the tender offer made by Adriatic Acquisition Corporation, a Delaware corporation ("Purchaser") and a wholly-owned subsidiary of GlaxoSmithKline plc, a public company organized under the laws of England and Wales ("Parent"), to purchase all of the issued and outstanding shares of TESARO, Inc., a Delaware corporation ("TESARO"), for $75.00 per share, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of December 3, 2018 by and among TESARO, Purchaser, and Parent (the "Merger Agreement"). Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 17:07 UTC | TESARO, Inc. TSRO · Entity 160894 | GrantDirector Restricted Stock Units · Derivative | 4,052 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-038343 · a4.xml · derivative · entry 3 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,052 Underlying: Common Stock · 4,052 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of TESARO common stock. F4 · derivative.exercise_date: The RSUs vest on the earlier of the one-year anniversary of the date of grant and the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's board of directors. F4 · derivative.expiration_date: The RSUs vest on the earlier of the one-year anniversary of the date of grant and the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 17:07 UTC | TESARO, Inc. TSRO · Entity 160894 | GrantDirector Nonqualified Stock Option (right to buy) · Derivative | 7,209 | $0.00 Strike: $46.89 | $0.00 |
DisclosureSEC source: 0001104659-18-038343 · a4.xml · derivative · entry 2 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,209 Underlying: Common Stock · 7,209 shares Expires 2028-06-01 F2 · derivative.exercise_date: The option vests on the earlier of the one-year anniversary of the date of grant and the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 17:07 UTC | TESARO, Inc. TSRO · Entity 160894 | GrantCommon Stock | 1,631 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-038343 · a4.xml · nonDerivative · entry 1 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,090 F1 · shares: The Reporting Person has elected to receive TESARO common stock in lieu of cash for board retainers and fees otherwise payable in cash. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 22:01 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (right to buy) · Derivative | 30,500 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0001144204-18-000856 · tv482714_4.xml · derivative · entry 1 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,500 Underlying: Common Stock · 30,500 shares Expires 2028-01-02 F1 · derivative.exercise_date: 10,500 of the shares will vest 1/48th on the first day of each month, commencing February 1, 2018, until the stock option becomes fully vested and exercisable. The remaining 20,000 shares will vest 1/12 on the first day of each month, commencing February 1, 2018, with the last month vesting on December 31, 2018. However, the option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 18:14 UTC | TESARO, Inc. TSRO · Entity 160894 | GrantDirector Nonqualified Stock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $149.22 | $0.00 |
DisclosureSEC source: 0001104659-17-037535 · a4.xml · derivative · entry 2 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2027-06-01 F2 · derivative.exercise_date: The option vests on the earlier of the one-year anniversary of the date of grant and the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 18:14 UTC | TESARO, Inc. TSRO · Entity 160894 | GrantCommon Stock | 459 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-037535 · a4.xml · nonDerivative · entry 1 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 459 F1 · shares: The Reporting Person has elected to receive common stock in lieu of cash for board retainers and fees otherwise payable in cash. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 02:41 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (right to buy) · Derivative | 28,560 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001144204-17-000700 · v456175_4.xml · derivative · entry 1 COLLIER EARL M JR · CIK 0001201254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,560 Underlying: Common Stock · 28,560 shares Expires 2027-01-03 F1 · derivative.exercise_date: 8,560 of the shares will vest 1/48th on the first day of each month, commencing February 1, 2017, until the stock option becomes fully vested and exercisable. The remaining 20,000 shares will vest 1/12 on the first day of each month, commencing February 1, 2017, with the last month vesting on December 31, 2017. However, the option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.